A multicenter, double-blind, randomized, parallel group study to evaluate the safety and efficacy of sitagliptin in elderly patients with type 2 diabetes mellitus.
Phase of Trial: Phase III
Latest Information Update: 15 May 2017
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2014 Results published in the Drugs and Aging.
- 23 Mar 2011 Results published in the Current Medical Research and Opinion.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History